How should urge urinary incontinence in adults be evaluated and managed?

Management of Urge Urinary Incontinence in Adults

Start with bladder training as first-line therapy for urge urinary incontinence, and if symptoms persist after an adequate trial, add antimuscarinic medications, selecting based on tolerability and side effect profile rather than efficacy since all agents work equally well. 1

Initial Evaluation

When assessing urge incontinence, focus your history on:

• Sudden, compelling urge to void that cannot be delayed
• Frequency of incontinence episodes and their impact on daily activities
• Presence of urgency, frequency, and nocturia
• Ruling out stress incontinence symptoms (leakage with cough, sneeze, or physical activity)
• Identifying risk factors: obesity, UTI, functional impairment, chronic cough, constipation 1

Basic workup should include:

• Urinalysis to exclude infection
• Post-void residual measurement
• Bladder diary (documents intake and voiding patterns)
• Validated symptom questionnaires to quantify severity and bother 2

Skip urodynamics, cystoscopy, and imaging in uncomplicated cases - these are not indicated for initial evaluation unless you have mixed incontinence, elevated post-void residual, suspected neurogenic dysfunction, or diagnostic uncertainty. 3

Treatment Algorithm

First-Line: Behavioral Therapies (All Patients)

Bladder training is the cornerstone - this involves scheduled voiding with progressive interval increases, urge suppression techniques, and delayed voiding strategies. 1

Combine with these behavioral modifications:

• Fluid management: 25% reduction in fluid intake reduces frequency and urgency 2
• Caffeine reduction: decreases voiding frequency 2
• Weight loss for obese patients: 8% weight loss reduces urgency incontinence episodes by 42% 2
• Pelvic floor muscle training: can be added to bladder training, though bladder training alone is equally effective for pure urgency incontinence 1

These behavioral therapies are as effective as antimuscarinic medications in reducing symptoms and have essentially zero adverse effects, making them mandatory first-line treatment. 2

Second-Line: Pharmacologic Therapy

Add antimuscarinic medications only after bladder training has failed. 1

All antimuscarinics have equal efficacy - there is no compelling evidence for differential effectiveness across medications. Choose based on tolerability, adverse effects, ease of use, and cost. 1, 2

Available agents (alphabetically, no hierarchy):

• Darifenacin
• Fesoterodine
• Oxybutynin
• Solifenacin
• Tolterodine
• Trospium

Critical tolerability differences:

• Lowest discontinuation rates (similar to placebo): Darifenacin and tolterodine 1
• Highest discontinuation rate: Oxybutynin (NNTH = 16, meaning 1 in 16 patients stops due to side effects) 1
• Solifenacin: Lowest risk for discontinuation among agents with higher discontinuation than placebo (NNTH = 78) 1

Common adverse effects to counsel patients about:

• Dry mouth (most common)
• Constipation
• Blurred vision
• Cognitive impairment (particularly concerning in elderly)
• Urinary retention 1, 2

Contraindications and cautions:

• Absolute contraindication: Narrow-angle glaucoma (unless cleared by ophthalmologist) 2
• Use with extreme caution: Impaired gastric emptying, history of urinary retention 2
• Monitor carefully: Post-void residual 250-300 mL 2

Alternative agent:

• Mirabegron (β-3 adrenoceptor agonist): Consider if anticholinergic side effects are problematic. Associated with nasopharyngitis and GI disorders rather than anticholinergic effects. 1, 4

Combination Therapy

Behavioral therapies may be combined with antimuscarinics for patients with partial response to either modality alone. 2

Common Pitfalls to Avoid

1. Don't use systemic pharmacologic therapy for stress incontinence - it doesn't work. If the patient has pure stress incontinence, refer for pelvic floor muscle training or surgical evaluation. 1

2. Don't skip behavioral therapy and jump to medications - behavioral interventions are equally or more effective than drugs with essentially no side effects. Starting with medications wastes an opportunity for effective, safe treatment. 2

3. Don't continue ineffective medications - adherence to pharmacologic treatment is poor, largely due to adverse effects. If a patient cannot tolerate one antimuscarinic, try another with a better tolerability profile rather than abandoning pharmacotherapy entirely. 1

4. Don't order urodynamics routinely - this is unnecessary in uncomplicated urge incontinence and adds cost without changing management. 2, 3

When to Consider Third-Line or Specialist Referral

For patients who fail both behavioral and pharmacologic therapy, consider:

• Neuromodulation (sacral or peripheral)
• Intravesical botulinum toxin injections
• Specialist urogynecology or urology evaluation 3, 4

These interventions require specialized training and are beyond primary care scope but offer superior efficacy to conservative management in refractory cases. 5